Ardelyx Share Price Today

Ardelyx class action deadline nears as CCO Foster named defendant

Eric Foster, Ardelyx Chief Commercial Officer, is named as an individual defendant in a securities class action lawsuit. The lead plaintiff deadline for the lawsuit is November 16, 2026, for investors who purchased shares between January 13, 2025, and August 6, 2026. The complaint alleges Foster assured investors that patient access was working while payer barriers were restricting IBSRELA and XPHOZAH prescriptions. ARDX stock fell approximately 18% following the August 6, 2026, announcement of reduced IBSRELA guidance and withdrawn XPHOZAH long-term projections.

Ardelyx Q3FY26 Results: Revenue misses estimates at $125.5 million

Total product revenue of $125.5 million missed consensus estimate by 2.27%. Revenue grew 19% YoY, with IBSRELA contributing $96.3 million (+23%). Net loss narrowed to $0.7 million from $1.0 million in prior year period. R&D expenses rose 39% YoY to $25.2 million due to ACCEL trial investments.

Rosen Law urges Ardelyx investors to act before Nov 16 deadline

Rosen Law Firm urges Ardelyx investors to secure counsel before the November 16, 2026 lead plaintiff deadline. The class action covers purchases between January 13, 2025 and August 6, 2026, alleging misleading statements on payer access. ARDX shares fell approximately 18% after the company reduced 2026 IBSRELA guidance and withdrew XPHOZAH projections.

Ardelyx Inc. to report Q3FY26 results on November 3, 2026

Ardelyx Inc. will host a conference call on November 3, 2026, to discuss Q3 2026 financial results. The webcast will begin at 4:30 pm ET and include a business update for the quarter. Access details for domestic and international dial-in are provided for investors.

Ardelyx data shows IBSRELA cuts GI healthcare resource use

Ardelyx Inc. presented real-world data at ACG 2026 showing reduced GI-HCRU after IBSRELA initiation. The analysis focused on adults with irritable bowel syndrome with constipation (IBS-C). Company also shared data on IBS-C symptom burden impact on quality of life. Details on ongoing Phase 3 study for chronic idiopathic constipation (CIC) were disclosed.

Ardelyx Q2FY26 Results: Revenue hits record $118M, IBSRELA guide cut

Ardelyx reported record Q2 2026 revenue of $118 million, up 31% YoY, with IBSRELA contributing $86.2 million and XPHOZAH $31.9 million. Full-year 2026 IBSRELA revenue guidance was lowered to $350-$370 million due to payer hurdles slowing new patient starts, while XPHOZAH guidance remained at $110-$120 million. Net loss narrowed to $16.7 million from $19.1 million in Q2 2025, supported by $281.8 million in cash and investments. Operating expenses rose significantly, with R&D at $26.1 million and SG&A at $101.4 million, reflecting investments in clinical trials and commercial access teams. The company withdrew its long-term $750 million revenue target for XPHOZAH but reaffirmed a path to sustained profitability in 2027.